NEW YORK (GenomeWeb) – Swedish drug discovery firm Pelago Bioscience and German proteomics firm OmicScouts today announced a collaboration to determine and quantify drug interactions using Pelago's cellular thermal shift assay (CETSA) technology.
Under the terms of the agreement, Pelago has licensed its CETSA technology to OmicScouts for mass spectrometric and proteomic applications for contract research projects. The firms will combine expertise and resources to offer target identification and validation services.
The firms said that they also plan to explore and develop CETSA for proteomics-based approaches for drug de-orphanization and biomarker discovery applications.
"CETSA with proteomic readout can nicely complement chemical proteomics techniques for target identification and offers unprecedented perspectives to study small molecule-protein interactions," Hannes Hahne, OmicScouts managing director, said in a statement.
Solna, Sweden-based Pelago CEO Michael Dabrowski added that mass spectrometry applications of CETSA technology could help both target-based and phenotypic screening-based drug discovery.
Financial terms of the agreement were not disclosed.